Gene Therapy
Portfolio includes five investigational gene therapy programs for glycogen storage disorders that have no existing FDA-approved treatments available Warden Bio Co-Founder Kunal Kishnani joins as President of Kriya’s Rare Disease Division and will lead its overall strategic, development, and partnership activities Excerpt from the Press Release: REDWOOD CITY, Calif. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Kriya…
Read More
Excerpt from the Press Release: – 33% Objective Response Rate (ORR) was observed in 33 RECIST evaluable patients across all FolRα expression levels and both dose levels. – Dose response was observed, with a 47% ORR in 17 patients who started at the 5.2 mg/kg dose level. – Tumor proportion score (TPS) was selected as…
Read More
The cancer therapy may also affect the protein building process, not just cause muscles to degrade Date:November 18, 2021 Source:Penn State Summary:Previous research has found that chemotherapy can trigger muscle loss in people living with cancer, but a new study out of found it may also affect the way the body builds new muscle —…
Read More
100 percent overall survival with median follow-up of two years post-treatment with HSC gene therapy Preliminary findings show promising metabolic and early clinical outcomes Results warrant further evaluation in global registrational study expected to be initiated in 2022 following recent meeting to discuss trial design with U.S. and European regulators Excerpt from the Press Release:…
Read More
Data indicate that gene therapy appears to be effective, particularly in neuroischemic ulcers Excerpt from the Press Release: SAN DIEGO, Oct. 22, 2021 /PRNewswire/ — Helixmith, a gene therapy company based in Seoul, Korea and San Diego, CA, announced today the results of a Phase 3 study for the treatment of diabetic foot ulcers with their novel gene therapy VM202 (Engensis)…
Read More- « Previous
- 1
- …
- 4
- 5
- 6